Advertisement Veristat, Molecular Templates enter into preferred provider agreement for refractory non-Hodgkin’s B-Cell Lymphoma trial - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Veristat, Molecular Templates enter into preferred provider agreement for refractory non-Hodgkin’s B-Cell Lymphoma trial

Veristat, a full service Clinical Research Organization (CRO), announced that Molecular Templates, a venture-backed biopharmaceutical company that develops next-generation immunotoxins for the treatment of cancer and other serious diseases, has entered into a Preferred Provider Agreement with Veristat.

"We are elated following the FDA’s approval of our IND application for MT-3724 and are eager to begin the next steps of our clinical journey with Veristat. Veristat will support the initiation of our Phase I program, which will assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of MT-3724 in patients with non-Hodgkin’s B-Cell Lymphoma who are resistant or refractory to all currently available therapies," commented Jason Kim, President and CFO, Molecular Templates.

Under this agreement, Veristat will provide a broad spectrum of clinical support given their depth of experience in oncology and work with novel therapeutics. Services will include clinical monitoring, safety management, data management, data monitoring committee services, statistics and medical writing support for the company’s lead compound, MT-3724. This compound is the first immunotoxin to target the B-cell specific CD20 surface antigen.

MT-3724 will enter clinical trials for the treatment of patients with relapsed non-Hodgkin’s lymphoma in the fourth quarter of 2014.

David Valacer, Chief Medical Officer, Molecular Templates stated, "By partnering with a like-minded, scientifically focused company such as Veristat, we have found a core team of high caliber collaborators who can help us to accelerate the development of our new class of targeted biologic therapies. This agreement with Veristat is a great step forward for our company given Veristat’s therapeutic and regulatory understanding of both the fundamental elements of clinical research and the broader impact of our work."

Barbara Balser VMD, Executive Vice President and Chief Scientific Officer of Veristat noted, "We are grateful to be chosen by Molecular Templates and look forward to a long and collaborative working relationship. Now that the FDA has cleared the path, the Veristat team can begin work on the Phase I study, an important milestone in the development of this compound. Our clinical team is focused on making a difference in the success of the program and we are honored to be able to contribute our expertise and support to the critical components of the clinical development of this important novel therapy."